These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26601869)

  • 1. Mucosal Melanoma: Epidemiology, Biology and Treatment.
    Spencer KR; Mehnert JM
    Cancer Treat Res; 2016; 167():295-320. PubMed ID: 26601869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
    Jung S; Johnson DB
    Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.
    Sergi MC; Filoni E; Triggiano G; Cazzato G; Internò V; Porta C; Tucci M
    Curr Oncol Rep; 2023 Nov; 25(11):1247-1258. PubMed ID: 37773078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal melanomas.
    Tomicic J; Wanebo HJ
    Surg Clin North Am; 2003 Apr; 83(2):237-52. PubMed ID: 12744608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis.
    Bishop KD; Olszewski AJ
    Int J Cancer; 2014 Jun; 134(12):2961-71. PubMed ID: 24272143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy for malignant melanoma].
    Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
    Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.
    Papaspyrou G; Garbe C; Schadendorf D; Werner JA; Hauschild A; Egberts F
    Melanoma Res; 2011 Dec; 21(6):475-82. PubMed ID: 21897303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acral melanoma foot lesions. Part 1: epidemiology, aetiology, and molecular pathology.
    Desai A; Ugorji R; Khachemoune A
    Clin Exp Dermatol; 2017 Dec; 42(8):845-848. PubMed ID: 28940724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality Imaging and Genetics of Primary Mucosal Melanomas and Response to Treatment.
    Saleh M; Javadi S; Elsherif S; Patnana M; Sagebiel TL; Torres-Cabala C; Mattei J; Bhosale P; Faria SC
    Radiographics; 2021; 41(7):1954-1972. PubMed ID: 34678102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary mucosal melanomas: a comprehensive review.
    Mihajlovic M; Vlajkovic S; Jovanovic P; Stefanovic V
    Int J Clin Exp Pathol; 2012; 5(8):739-53. PubMed ID: 23071856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
    Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal melanoma: a clinically and biologically unique disease entity.
    Carvajal RD; Spencer SA; Lydiatt W
    J Natl Compr Canc Netw; 2012 Mar; 10(3):345-56. PubMed ID: 22393195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
    Rajkumar S; Watson IR
    Br J Cancer; 2016 Jul; 115(2):145-55. PubMed ID: 27336610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
    Mao L; Qi Z; Zhang L; Guo J; Si L
    Front Immunol; 2021; 12():680407. PubMed ID: 34149718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on primary mucosal melanoma.
    Tacastacas JD; Bray J; Cohen YK; Arbesman J; Kim J; Koon HB; Honda K; Cooper KD; Gerstenblith MR
    J Am Acad Dermatol; 2014 Aug; 71(2):366-75. PubMed ID: 24815565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal melanoma of the head and neck.
    Ascierto PA; Accorona R; Botti G; Farina D; Fossati P; Gatta G; Gogas H; Lombardi D; Maroldi R; Nicolai P; Ravanelli M; Vanella V
    Crit Rev Oncol Hematol; 2017 Apr; 112():136-152. PubMed ID: 28325255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.